Kidney Failure, Chronic Clinical Trial
Official title:
Effect of Probiotics on Modulating the Bacterial Translocation and Improving Micro-inflammation in Hemodialysis Patients
Intestinal microbiota has recently emerged as an important player in the progression and complications of chronic kidney disease(CKD). And drug therapy which selects the gut as a target has raised lots of concern. It has been reported that the composition of intestinal flora has changed in uremic patients. Specifically, imbalanced ecosystem has higher number of pathogens such as Clostridia, Enterobacteria,and lower number of beneficial microbes such as Lactobacilli and Bifidobacteria. This modification of intestinal flora can strongly increase transformation of amino acids into Uremic Retention solutes, e.g., indoxyl-sulfate (IS), p-cresyl sulfate (PCS), which are so called gut-derived uremic toxins. The dysbiosis also contributes to an increase in intestinal permeability by disrupting the colonic epithelial tight junction,which may subsequently lead to translocation of endotoxin and bacteria into the host's internal environment,resulting in systemic micro-inflammation.Also all of these can promote the progression of renal failure and the incidence of cardiovascular complications,renal osteodystrophy and anemia.Probiotics is defined by the World Health Organization as 'live microorganisms that, when administered in adequate amounts, confer a health benefit on the host'. Probiotics are being increasingly used for various pathologic conditions.It is said that probiotics have a therapeutic role in maintaining a metabolically balanced gastrointestinal tract (GIT).And in our previous study,the investigators found that in uremic rats,lactobacillus acidophilus can relieve bacterial translocation and decrease the level of inflammatory markers.So our study is mainly designed to investigate whether probiotics can modulate the balance of intestinal ecosystem, prevent the bacterial translocation from gut and alleviate the systemic inflammation in hemodialysis(HD) patients.
This study is a single-centre, double-blind, placebo-controlled, randomised trial.
Participants will undergo a 2 week run-in period, followed by randomisation to either
probiotics supplements or placebo for 6 months. The study population are hemodialysis
patients from Dialysis Department in First Affiliated Hospital of Xi'an Jiaotong University.
The Dialysis Department have 400 patients who regularly come to receive dialysis therapy
three times a week.It's relatively easy for us to follow up and collect data.Patients who
meet the criteria and are able to provide informed consent will be recruited.Then
computer-generated randomisation of participants to treatment order will be undertaken by an
external statistical consultant. This process of allocation will conceal the randomisation
order to researchers and participants. In addition, the supplements will be packed off-site
with a generic label.
After randomization,baseline data will be collected and all participants will undergo
face-to-face dietary education with a dietitian, incorporating standard hemodialysis
education during the first week of run-in.In the week following, and throughout the
intervention, patients will be encouraged to maintain stable protein and fibre intakes, with
specific attention to maintaining the same sources of these nutrients.Participants' dietary
intakes during the study will be assessed every month using a semi-quantitative food
frequency questionnaire. And when the trial starts, questionnaires and biological samples
will be performed and collected at the corresponding time. All serious adverse events will be
reported to the ethics committee, whether deemed to be intervention related or not. Adherence
to supplements will be measured by pill count every two weeks.
This study is an explorative clinical trial.And in the absence of any data about the effect
of probiotics on hemodialysis patients intestinal and serum microbiota,sample size can't be
calculated.Data will be reported as s mean±SD if normally distributed and as median(25-75%
percentiles) if not. The Shapiro-Wilk test is performed to assess whether data are normally
distributed. Statistical comparisons of normally distributed data are performed using
Student's t-test. Mann-Whitney U-test is used to compare the rank variables measuring
gastrointestinal symptoms in probiotics and placebo groups. The threshold for statistical
significance is at p values <0.05. And an external statistical consultant from our Clinical
Research Center will be involved in the data validation and analysis activities.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |